These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 28806393

  • 1. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
    Jain P, Fierst TM, Han HJ, Smith TE, Vakil A, Storm PB, Resnick AC, Waanders AJ.
    Oncogene; 2017 Nov 09; 36(45):6348-6358. PubMed ID: 28806393
    [Abstract] [Full Text] [Related]

  • 2. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.
    Jain P, Silva A, Han HJ, Lang SS, Zhu Y, Boucher K, Smith TE, Vakil A, Diviney P, Choudhari N, Raman P, Busch CM, Delaney T, Yang X, Olow AK, Mueller S, Haas-Kogan D, Fox E, Storm PB, Resnick AC, Waanders AJ.
    Oncotarget; 2017 Oct 17; 8(49):84697-84713. PubMed ID: 29156677
    [Abstract] [Full Text] [Related]

  • 3. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.
    Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC.
    Proc Natl Acad Sci U S A; 2013 Apr 09; 110(15):5957-62. PubMed ID: 23533272
    [Abstract] [Full Text] [Related]

  • 4. BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers.
    Jain P, Surrey LF, Straka J, Russo P, Womer R, Li MM, Storm PB, Waanders AJ, Hogarty MD, Resnick AC, Picarsic J.
    Pediatr Blood Cancer; 2021 Jun 09; 68(6):e28933. PubMed ID: 33565241
    [Abstract] [Full Text] [Related]

  • 5. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells.
    Usta D, Sigaud R, Buhl JL, Selt F, Marquardt V, Pauck D, Jansen J, Pusch S, Ecker J, Hielscher T, Vollmer J, Sommerkamp AC, Rubner T, Hargrave D, van Tilburg CM, Pfister SM, Jones DTW, Remke M, Brummer T, Witt O, Milde T.
    Mol Cancer Ther; 2020 Aug 09; 19(8):1736-1750. PubMed ID: 32451331
    [Abstract] [Full Text] [Related]

  • 6. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
    Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Stalpers LJ, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA.
    Clin Cancer Res; 2016 Nov 01; 22(21):5312-5321. PubMed ID: 27217440
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL.
    Cancer Cell; 2015 Sep 14; 28(3):384-98. PubMed ID: 26343583
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
    Wang P, Laster K, Jia X, Dong Z, Liu K.
    Mol Cancer; 2023 Dec 18; 22(1):208. PubMed ID: 38111008
    [Abstract] [Full Text] [Related]

  • 11. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF.
    Yuan J, Ng WH, Yap J, Chia B, Huang X, Wang M, Hu J.
    J Biol Chem; 2018 Sep 14; 293(37):14276-14284. PubMed ID: 30030377
    [Abstract] [Full Text] [Related]

  • 12. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
    Chatelle CV, Hövermann D, Müller A, Wagner HJ, Weber W, Radziwill G.
    Sci Rep; 2016 Mar 30; 6():23713. PubMed ID: 27025703
    [Abstract] [Full Text] [Related]

  • 13. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 14. Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling.
    Cope NJ, Novak B, Liu Z, Cavallo M, Gunderwala AY, Connolly M, Wang Z.
    J Biol Chem; 2020 Feb 21; 295(8):2407-2420. PubMed ID: 31929109
    [Abstract] [Full Text] [Related]

  • 15. A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma.
    Yde CW, Sehested A, Mateu-Regué À, Østrup O, Scheie D, Nysom K, Nielsen FC, Rossing M.
    Cancer Genet; 2016 Oct 21; 209(10):440-444. PubMed ID: 27810072
    [Abstract] [Full Text] [Related]

  • 16. Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase.
    Rohrer L, Spohr C, Beha C, Griffin R, Braun S, Halbach S, Brummer T.
    Cell Commun Signal; 2023 Jun 14; 21(1):136. PubMed ID: 37316874
    [Abstract] [Full Text] [Related]

  • 17. Spinal Pleomorphic Xanthoastrocytoma With a QKI-RAF1 Fusion.
    Daoud EV, Wachsmann M, Richardson TE, Mella D, Pan E, Schwarzbach A, Oliver D, Hatanpaa KJ.
    J Neuropathol Exp Neurol; 2019 Jan 01; 78(1):10-14. PubMed ID: 30517658
    [Abstract] [Full Text] [Related]

  • 18. Novel RAF Fusions in Pediatric Low-Grade Gliomas Demonstrate MAPK Pathway Activation.
    Lind KT, Chatwin HV, DeSisto J, Coleman P, Sanford B, Donson AM, Davies KD, Willard N, Ewing CA, Knox AJ, Mulcahy Levy JM, Gilani A, Green AL.
    J Neuropathol Exp Neurol; 2021 Dec 29; 80(12):1099-1107. PubMed ID: 34850053
    [Abstract] [Full Text] [Related]

  • 19. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS, Jung M, Kang HN, Kim H, Park CW, Kim SM, Shin SJ, Kim SH, Kim SG, Kim EK, Yun MR, Zheng Z, Chung KY, Greenbowe J, Ali SM, Kim TM, Cho BC.
    Oncogene; 2017 Jun 08; 36(23):3334-3345. PubMed ID: 28092667
    [Abstract] [Full Text] [Related]

  • 20. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
    Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, Stavropoulos J, Alon N, Pole JD, Ray PN, Navickiene V, Mangerel J, Remke M, Buczkowicz P, Ramaswamy V, Guerreiro Stucklin A, Li M, Young EJ, Zhang C, Castelo-Branco P, Bakry D, Laughlin S, Shlien A, Chan J, Ligon KL, Rutka JT, Dirks PB, Taylor MD, Greenberg M, Malkin D, Huang A, Bouffet E, Hawkins CE, Tabori U.
    J Clin Oncol; 2015 Mar 20; 33(9):1015-22. PubMed ID: 25667294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.